Johnson & Johnson (NYSE:JNJ) Shares Purchased by Dimensional Fund Advisors LP

Key Points

• Dimensional Fund Advisors LP increased its ownership in Johnson & Johnson by 14.4%, acquiring an additional 2,129,612 shares, bringing its total to 16,903,105 shares, valued at approximately $2.8 billion.
• Johnson & Johnson reported Q2 earnings of $2.77 per share, exceeding the expected $2.68, and had a revenue of $23.74 billion, up 5.8% from last year.
• The company declared a quarterly dividend of $1.30, with an annualized dividend of $5.20, representing a yield of 3.0%, to be paid on September 9th.

Dimensional Fund Advisors LP increased its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 14.4% in the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 16,903,105 shares of the company's stock after buying an additional 2,129,612 shares during the period. Johnson & Johnson comprises approximately 0.7% of Dimensional Fund Advisors LP's investment portfolio, making the stock its 11th biggest holding. Dimensional Fund Advisors LP owned about 0.70% of Johnson & Johnson worth $2,803,042,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Johnson & Johnson by 13.9% in the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after acquiring an additional 6,332 shares during the period. Hudson Value Partners LLC increased its position in shares of Johnson & Johnson by 2.5% in the 4th quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock valued at $5,648,000 after acquiring an additional 1,022 shares during the period. Jump Financial LLC increased its position in shares of Johnson & Johnson by 2,001.9% in the 4th quarter. Jump Financial LLC now owns 31,717 shares of the company's stock valued at $4,587,000 after acquiring an additional 30,208 shares during the period. Wasatch Advisors LP increased its position in shares of Johnson & Johnson by 5.9% in the 4th quarter. Wasatch Advisors LP now owns 41,954 shares of the company's stock valued at $6,067,000 after acquiring an additional 2,338 shares during the period. Finally, Capital Square LLC increased its position in shares of Johnson & Johnson by 16.9% in the 4th quarter. Capital Square LLC now owns 5,868 shares of the company's stock valued at $862,000 after acquiring an additional 848 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have commented on JNJ. Bank of America upped their price target on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a report on Thursday, July 17th. UBS Group upped their price target on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Barclays upped their price target on shares of Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Royal Bank Of Canada upped their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the company an "outperform" rating in a report on Thursday, July 17th. Finally, Morgan Stanley upped their price target on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Nine investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $174.50.

Johnson & Johnson Price Performance

JNJ traded up $2.04 during trading on Friday, reaching $176.76. The company's stock had a trading volume of 9,476,237 shares, compared to its average volume of 8,427,234. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a fifty day simple moving average of $161.28 and a two-hundred day simple moving average of $158.34. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $177.27. The company has a market cap of $425.70 billion, a price-to-earnings ratio of 18.90, a PEG ratio of 2.23 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts' consensus estimates of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business's revenue was up 5.8% on a year-over-year basis. During the same period last year, the company posted $2.82 EPS. As a group, analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be issued a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.